IMT-2021-0145 Supplementary Tables

Supplementary Table
1. 1L treatments received by treatment class (N=501)

Supplementary Table
2. Reasons for end of follow-up for patients who did not receive 2L treatment

Supplementary Table
3. Subgroup analysis of median OS (N=501)

Supplementary Table
4. Adjusted cox regression analysis of treatment outcomes for 1L treatment
groups

Background

We
report real-world treatment patterns and outcomes in patients with PD-L1+
NSCLC.

Methods

This
retrospective, observational study using the ConcertAI Oncology Dataset,
included patients with PD-L1+ (≥1% expression) metastatic NSCLC who began
first-line (1L) treatment between 2016-2019. Treatment outcomes were assessed
by treatment class (immune checkpoint inhibitor [ICI] monotherapy, ICI
combinations, or chemotherapy).

Results

In total, 128 (25.5%), 237 (47.3%) and 136
patients (27.1%) received 1L chemotherapy, 1L ICI monotherapy, and 1L ICI
combinations, respectively. ICI combinations and monotherapy had improved
clinical outcomes vs chemotherapy. Adjusted analyses showed no significant
difference in outcome between ICI monotherapy and ICI combinations.

Conclusion

ICI-based treatments are being increasingly
adopted into clinical practice and were associated with better outcomes vs
chemotherapy.